Avance Clinical has announced the opening of new clinical operations in Seoul, South Korea. Avance Clinical CEO, Yvonne Lungershausen said the decision to open clinical operations in Seoul followed increasing demand from later phase US biotechs, as well as CRO partners for access to the region’s scientific excellence and patient populations.

“In addition, feedback from a recent presentation of our GlobalReady drug development solution to more than 75 Korean biotechs and pharmaceutical companies in Seoul showed a real need for Korean clinical operations with a global pathway,” said Lungershausen.

“The new South Korean operations also offer a strategic presence for Avance Clinical’s CRO partners conducting multi-regional or global trials. In addition, Korean biotechs are utilising our Australian and United States clinical services as they progress their drug development programmes,” said Lungershausen.

Avance Clinical is focussed on accelerating drug development for its biotech clients, from preclinical stages through to Phase III.